SCHEDULE 13G: Anson Funds Discloses 9.9% Stake in Transcode Therapeutics

Anson Funds Management LP and affiliated entities have disclosed a 9.9% beneficial ownership stake in Transcode Therapeutics, Inc., comprising 113,479 shares of common stock.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam collectively reported beneficial ownership of 113,479 shares of Transcode Therapeutics, Inc. Common Stock.
• This represents 9.9% of the company's outstanding Common Stock.
• The ownership includes shares of Common Stock underlying outstanding warrants, subject to a beneficial ownership limitation preventing exercise beyond 9.99% of outstanding Common Stock.
• The percentage is calculated based on 1,029,095 shares issued and outstanding as of February 4, 2024, plus 106,838 shares receivable from warrant exercise, totaling 1,135,933 shares.
• Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors to the private fund holding these shares, with shared voting and dispositive power.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment about the company's performance or future prospects. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant institutional investment in Transcode Therapeutics, Inc., a company operating in the biotechnology sector. Such disclosures are common for investment firms acquiring substantial stakes, signaling their belief in the company's long-term prospects or a strategic investment.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Anson Funds may be viewed positively, indicating confidence from a professional investor, potentially influencing market perception and share price.
• Company Management: Awareness of a large institutional holder may influence strategic decisions or engagement with the investor.

Key Dates

Keywords

Transcode Therapeutics, Anson Funds Management, Anson Advisors, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Warrants, Institutional Investor, Biotechnology, Healthcare